Da Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Da Li has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Junting Zhang
Beijing Tiantan Hospital, Capital Medical University
17 shared publications Li-Wei Zhang
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
11 shared publications- Zhen Wu
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
11 shared publications Liang Wang
Beijing Tiantan Hospital, Capital Medical University
10 shared publicationsZhen Wu
16Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
9 shared publicationsGui-Jun Zhang
Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
7 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049628
Association Between Pregnancy and Symptomatic Hemorrhage in Women With Brainstem Cavernous Malformations and Bleeding in the Preceding Year: A Prospective Multicenter Study
Background: The association between pregnancy and the risk of symptomatic hemorrhage (SH) in brainstem cavernous malformations remains uncertain. We aimed to quantify the risk of pregnancy‐associated SH in women with brainstem cavernous malformations. Methods: We analyzed women with brainstem cavernous malformations in a prospective registry (2016–2022) experiencing pregnancy after enrollment. Follow‐up was divided into pregnancy‐associated segments (pregnancy plus ≤6 weeks postpartum or postabortion) and nonpregnant segments. Primary analysis used case‐crossover models; propensity score‐matched analyses assessed robustness. Results: Among 63 women (median age, 30.0 years), 53 (84.1%) had bled before enrollment, including 45 (71.4%) with SH in the preceding year. Prospectively, they contributed 72 pregnancies and 371.7 patient‐years, observing 34 SHs. The pregnancy annual SH rate was 20.4% versus 7.2% nonpregnant (adjusted incidence rate ratio: 2.56, 95% CI, 1.11–5.93; P =0.028). Trimester‐specific and postpartum annual SH rates were 5.9%, 16.8%, 34.6%, and 38.3%; risk significantly increased only during the third trimester ( P =0.004) and postpartum ( P =0.007). This pregnancy effect was confined to segments with SH in the preceding year (annual SH rates 46.7% versus 9.4%; P =0.007), which was an independent risk factor. Propensity score‐matched analyses yielded consistent results. Conclusions: Pregnancy is associated with an elevated SH risk in women with brainstem cavernous malformations, specifically among those with SH in the preceding year. Because of selection bias, generalizability to asymptomatic or incidental lesions is limited, warranting cautious extrapolation. Registration: URL: www.chictr.org.cn ; Unique Identifier: ChiCTR‐POC‐17011575.
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049628
Open AccessAssociation Between Pregnancy and Symptomatic Hemorrhage in Women With Brainstem Cavernous Malformations and Bleeding in the Preceding Year: A Prospective Multicenter Study
Background: The association between pregnancy and the risk of symptomatic hemorrhage (SH) in brainstem cavernous malformations remains uncertain. We aimed to quantify the risk of pregnancy‐associated SH in women with brainstem cavernous malformations. Methods: We analyzed women with brainstem cavernous malformations in a prospective registry (2016–2022) experiencing pregnancy after enrollment. Follow‐up was divided into pregnancy‐associated segments (pregnancy plus ≤6 weeks postpartum or postabortion) and nonpregnant segments. Primary analysis used case‐crossover models; propensity score‐matched analyses assessed robustness. Results: Among 63 women (median age, 30.0 years), 53 (84.1%) had bled before enrollment, including 45 (71.4%) with SH in the preceding year. Prospectively, they contributed 72 pregnancies and 371.7 patient‐years, observing 34 SHs. The pregnancy annual SH rate was 20.4% versus 7.2% nonpregnant (adjusted incidence rate ratio: 2.56, 95% CI, 1.11–5.93; P =0.028). Trimester‐specific and postpartum annual SH rates were 5.9%, 16.8%, 34.6%, and 38.3%; risk significantly increased only during the third trimester ( P =0.004) and postpartum ( P =0.007). This pregnancy effect was confined to segments with SH in the preceding year (annual SH rates 46.7% versus 9.4%; P =0.007), which was an independent risk factor. Propensity score‐matched analyses yielded consistent results. Conclusions: Pregnancy is associated with an elevated SH risk in women with brainstem cavernous malformations, specifically among those with SH in the preceding year. Because of selection bias, generalizability to asymptomatic or incidental lesions is limited, warranting cautious extrapolation. Registration: URL: www.chictr.org.cn ; Unique Identifier: ChiCTR‐POC‐17011575.
- 3 January 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 262, 109310
Combinations of clinical factors and radiomics for the hemorrhage-free survival of brainstem cavernous malformation patients
- 3 January 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 262, 109310
Combinations of clinical factors and radiomics for the hemorrhage-free survival of brainstem cavernous malformation patients
- Open Access
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43888
Surgical management and adverse factors for recurrence and long-term survival in adenoid cystic carcinoma patients with intracranial extension: A retrospective cohort study
Limited data regarding intracranial adenoid cystic carcinomas (ACCs) were available. The authors aimed to elaborate on the clinical characteristics, treatment strategy, and poor outcomes of the disease. Clinical data from all cases of intracranial ACCs treated at our institute were reviewed retrospectively to evaluate their clinical characteristics, management, and outcomes. our series included 10 males and 9 females, with a mean age of 47.3 years. The most common presentations were cranial neuropathies (11 cases), followed by headache (4 cases), and nasal symptoms (4 cases). The radiologic spectrum for intracranial ACCs was broad. Gross total resection (GTR), subtotal resection, and partial resection were performed in 8 (42.1%), 6 (31.6%) and 5 (26.3%) patients, respectively. After a median follow-up of 35.0 months (range, 3.0–89.0 months), 8 patients (42.1%) died. The 1-, 3-, and 5-year rates of progression-free survival and overall survival were 89.2%, 57.3%, and 20.5% and 89.5%, 57.5%, and 32.9%, respectively. Although the differences were not significantly different, GTR and the use of radiotherapy and chemotherapy tended to improve the prognosis of the patients. Intracranial ACCs are rare neoplasms. GTR alone, if tolerable, is advocated as the optimal treatment for intracranial ACCs. Nevertheless, conservative excision may be preferred to avoid damage to vital structures. Radiotherapy and chemotherapy may be an alternative treatment. Intracranial ACCs tend to recur or metastasis within a few years of the initial surgery.
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43888
Open AccessSurgical management and adverse factors for recurrence and long-term survival in adenoid cystic carcinoma patients with intracranial extension: A retrospective cohort study
Limited data regarding intracranial adenoid cystic carcinomas (ACCs) were available. The authors aimed to elaborate on the clinical characteristics, treatment strategy, and poor outcomes of the disease. Clinical data from all cases of intracranial ACCs treated at our institute were reviewed retrospectively to evaluate their clinical characteristics, management, and outcomes. our series included 10 males and 9 females, with a mean age of 47.3 years. The most common presentations were cranial neuropathies (11 cases), followed by headache (4 cases), and nasal symptoms (4 cases). The radiologic spectrum for intracranial ACCs was broad. Gross total resection (GTR), subtotal resection, and partial resection were performed in 8 (42.1%), 6 (31.6%) and 5 (26.3%) patients, respectively. After a median follow-up of 35.0 months (range, 3.0–89.0 months), 8 patients (42.1%) died. The 1-, 3-, and 5-year rates of progression-free survival and overall survival were 89.2%, 57.3%, and 20.5% and 89.5%, 57.5%, and 32.9%, respectively. Although the differences were not significantly different, GTR and the use of radiotherapy and chemotherapy tended to improve the prognosis of the patients. Intracranial ACCs are rare neoplasms. GTR alone, if tolerable, is advocated as the optimal treatment for intracranial ACCs. Nevertheless, conservative excision may be preferred to avoid damage to vital structures. Radiotherapy and chemotherapy may be an alternative treatment. Intracranial ACCs tend to recur or metastasis within a few years of the initial surgery.
- 18 June 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
QSM predicts haemorrhage risk in brainstem cavernous malformations: a multicentre prospective study
Background This study investigates the predictive value of baseline quantitative susceptibility mapping (QSM) metrics for assessing the risk of future symptomatic haemorrhages in patients with brainstem cavernous malformations (CMs). Methods From July 2020 to September 2023, a prospective multicentre cohort of 155 patients with brainstem CMs was enrolled from 12 institutions. We analysed baseline QSM metrics, including lesional mean, median, IQR and maximum susceptibility. Propensity score matching was adjusted for baseline confounders, and Cox regression models assessed haemorrhage risk. Risk stratification was performed based on thresholds determined from planned receiver operating characteristic (ROC) analyses. Results Postmatching cohorts (56 haemorrhage-free vs 30 haemorrhage cases) showed balanced baseline characteristics. Over a mean follow-up of 22.6 months, the baseline QSM metrics, particularly the median susceptibility (QSMmedian) (HR 58.896, 95% CI 8.544 to 405.989, pConclusions This study explored the predictive value of QSM metrics for future symptomatic haemorrhage, suggesting that QSM may serve as a complementary imaging biomarker to existing prognostic models. Further validation in larger, independent cohorts is warranted.
- 18 June 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
QSM predicts haemorrhage risk in brainstem cavernous malformations: a multicentre prospective study
Background This study investigates the predictive value of baseline quantitative susceptibility mapping (QSM) metrics for assessing the risk of future symptomatic haemorrhages in patients with brainstem cavernous malformations (CMs). Methods From July 2020 to September 2023, a prospective multicentre cohort of 155 patients with brainstem CMs was enrolled from 12 institutions. We analysed baseline QSM metrics, including lesional mean, median, IQR and maximum susceptibility. Propensity score matching was adjusted for baseline confounders, and Cox regression models assessed haemorrhage risk. Risk stratification was performed based on thresholds determined from planned receiver operating characteristic (ROC) analyses. Results Postmatching cohorts (56 haemorrhage-free vs 30 haemorrhage cases) showed balanced baseline characteristics. Over a mean follow-up of 22.6 months, the baseline QSM metrics, particularly the median susceptibility (QSMmedian) (HR 58.896, 95% CI 8.544 to 405.989, pConclusions This study explored the predictive value of QSM metrics for future symptomatic haemorrhage, suggesting that QSM may serve as a complementary imaging biomarker to existing prognostic models. Further validation in larger, independent cohorts is warranted.
- 23 November 2023
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- Vol. 102 (1) , 1-12
Hemorrhagic Outcome of Brainstem Cavernous Malformations following Radiosurgery: Dose-Response Relationship
Introduction: This study aimed to assess the impact of gamma knife radiosurgery on brainstem cavernous malformations (CMs). Methods: A total of 85 patients (35 females; median age 41.0 years) who underwent gamma knife radiosurgery for brainstem CMs at our institute between 2006 and 2015 were enrolled in a prospective clinical observation trial. Risk factors for hemorrhagic outcomes were evaluated, and outcomes were compared across different margin doses. Results: The pre-radiosurgery annual hemorrhage rate (AHR) was 32.3% (44 hemorrhages during 136.2 patient-years). The median planning target volume was 1.292 cc. The median margin and maximum doses were 15.0 and 29.2 Gy, respectively, with a median isodose line of 50.0%. The post-radiosurgery AHR was 2.7% (21 hemorrhages during 769.9 patient-years), with a rate of 5.5% within the first 2 years and 2.0% thereafter. The post-radiosurgery AHR for patients with margin doses of ≤13.0 Gy (n = 15), 14.0–15.0 Gy (n = 50), and ≥16.0 Gy (n = 20) was 5.4, 2.7, and 0.6%, respectively. Correspondingly, transient adverse radiation effects were observed in 6.7 (1/15), 10.0 (5/50), and 30.0% (6/20) of cases, respectively. An increased margin dose per 1 Gy (hazard ratio: 0.530, 95% CI: 0.341–0.826, p = 0.005) was identified as an independent protective factor against post-radiosurgery hemorrhage. Margin doses of ≥16.0 Gy were associated with improved hemorrhagic outcomes (hazard ratio: 0.343, 95% confidence interval [CI]: 0.157–0.749, p = 0.007), but an increased risk of adverse radiation effects (odds ratio: 3.006, 95% CI: 1.041–8.677, p = 0.042). Conclusion: The AHR of brainstem CMs decreased following radiosurgery, and our study revealed a significant dose-response relationship. Margin doses of 14–15 Gy were recommended. Further studies are required to validate our findings.
- 23 November 2023
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- Vol. 102 (1) , 1-12
Hemorrhagic Outcome of Brainstem Cavernous Malformations following Radiosurgery: Dose-Response Relationship
Introduction: This study aimed to assess the impact of gamma knife radiosurgery on brainstem cavernous malformations (CMs). Methods: A total of 85 patients (35 females; median age 41.0 years) who underwent gamma knife radiosurgery for brainstem CMs at our institute between 2006 and 2015 were enrolled in a prospective clinical observation trial. Risk factors for hemorrhagic outcomes were evaluated, and outcomes were compared across different margin doses. Results: The pre-radiosurgery annual hemorrhage rate (AHR) was 32.3% (44 hemorrhages during 136.2 patient-years). The median planning target volume was 1.292 cc. The median margin and maximum doses were 15.0 and 29.2 Gy, respectively, with a median isodose line of 50.0%. The post-radiosurgery AHR was 2.7% (21 hemorrhages during 769.9 patient-years), with a rate of 5.5% within the first 2 years and 2.0% thereafter. The post-radiosurgery AHR for patients with margin doses of ≤13.0 Gy (n = 15), 14.0–15.0 Gy (n = 50), and ≥16.0 Gy (n = 20) was 5.4, 2.7, and 0.6%, respectively. Correspondingly, transient adverse radiation effects were observed in 6.7 (1/15), 10.0 (5/50), and 30.0% (6/20) of cases, respectively. An increased margin dose per 1 Gy (hazard ratio: 0.530, 95% CI: 0.341–0.826, p = 0.005) was identified as an independent protective factor against post-radiosurgery hemorrhage. Margin doses of ≥16.0 Gy were associated with improved hemorrhagic outcomes (hazard ratio: 0.343, 95% confidence interval [CI]: 0.157–0.749, p = 0.007), but an increased risk of adverse radiation effects (odds ratio: 3.006, 95% CI: 1.041–8.677, p = 0.042). Conclusion: The AHR of brainstem CMs decreased following radiosurgery, and our study revealed a significant dose-response relationship. Margin doses of 14–15 Gy were recommended. Further studies are required to validate our findings.
- 27 March 2023
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-15
Surgical management and outcome of primary intracranial Rosai-Dorfman disease: a single-institute experience and pooled analysis of individual patient data
Primary intracranial Rosai-Dorfman disease (PIRDD) is considered a nonmalignant nonneoplastic entity, and the outcome is unclear due to its rarity. The study aimed to elaborate the clinic-radiological features, treatment strategies, and progression-free survival (PFS) in patients with PIRDD. Patients with pathologically confirmed PIRDD in our institute were reviewed. Literature of PIRDD, updated until December 2019, was systematically searched in 7 databases (Embase, PubMed, Cochrane database, Web of Science, Wanfang Data Knowledge Service Platform, the VIP Chinese Science and Technology Periodical Database (VIP), and the China National Knowledge Infrastructure (CNKI)). These prior publication data were processed and used according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Clinical-radiological characteristics and adverse factors for PFS were evaluated in the pooled cohort. The pooled cohort of 124 cases (81 male and 43 female), with a mean age of 39.7 years, included 11 cases from our cohort and 113 cases from 80 prior studies. Twenty-nine patients (23.4%) had multiple lesions. Seventy-four patients (59.7%) experienced gross total resection (GTR), 50 patients (40.3%) had non-GTR, 15 patients (12.1%) received postoperative adjuvant radiation, and 23 patients (18.5%) received postoperative steroids. A multivariate Cox regression revealed that GTR (HR = 4.52; 95% CI 1.21–16.86; p = 0.025) significantly improved PFS, and multiple lesions (p = 0.060) tended to increase the hazard of recurrence. Neither radiation (p = 0.258) nor steroids (p = 0.386) were associated with PFS. The overall PFS at 3, 5, and 10 years in the pooled cohort was 88.4%, 79.4%, and 70.6%, respectively. The PFS at 5 and 10 years in patients with GTR was 85.4% and 85.4%, respectively, which was 71.5% and 35.8%, respectively, in patients without GTR. Gross total resection significantly improved PFS and was recommended for PIRDD. Radiation and steroids were sometimes empirically administered for residual, multiple, or recurrent PIRDD, but the effectiveness remained arguable and required further investigation. Systematic review registration number: CRD42020151294.
- 27 March 2023
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-15
Surgical management and outcome of primary intracranial Rosai-Dorfman disease: a single-institute experience and pooled analysis of individual patient data
Primary intracranial Rosai-Dorfman disease (PIRDD) is considered a nonmalignant nonneoplastic entity, and the outcome is unclear due to its rarity. The study aimed to elaborate the clinic-radiological features, treatment strategies, and progression-free survival (PFS) in patients with PIRDD. Patients with pathologically confirmed PIRDD in our institute were reviewed. Literature of PIRDD, updated until December 2019, was systematically searched in 7 databases (Embase, PubMed, Cochrane database, Web of Science, Wanfang Data Knowledge Service Platform, the VIP Chinese Science and Technology Periodical Database (VIP), and the China National Knowledge Infrastructure (CNKI)). These prior publication data were processed and used according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Clinical-radiological characteristics and adverse factors for PFS were evaluated in the pooled cohort. The pooled cohort of 124 cases (81 male and 43 female), with a mean age of 39.7 years, included 11 cases from our cohort and 113 cases from 80 prior studies. Twenty-nine patients (23.4%) had multiple lesions. Seventy-four patients (59.7%) experienced gross total resection (GTR), 50 patients (40.3%) had non-GTR, 15 patients (12.1%) received postoperative adjuvant radiation, and 23 patients (18.5%) received postoperative steroids. A multivariate Cox regression revealed that GTR (HR = 4.52; 95% CI 1.21–16.86; p = 0.025) significantly improved PFS, and multiple lesions (p = 0.060) tended to increase the hazard of recurrence. Neither radiation (p = 0.258) nor steroids (p = 0.386) were associated with PFS. The overall PFS at 3, 5, and 10 years in the pooled cohort was 88.4%, 79.4%, and 70.6%, respectively. The PFS at 5 and 10 years in patients with GTR was 85.4% and 85.4%, respectively, which was 71.5% and 35.8%, respectively, in patients without GTR. Gross total resection significantly improved PFS and was recommended for PIRDD. Radiation and steroids were sometimes empirically administered for residual, multiple, or recurrent PIRDD, but the effectiveness remained arguable and required further investigation. Systematic review registration number: CRD42020151294.
- Open Access
SERPINF1 Mediates Tumor Progression and Stemness in Glioma
Serpin family F member 1 (SERPINF1) reportedly plays multiple roles in various tumors; however, its clinical significance and molecular functions in glioma have been largely understudied. In the present study, we analyzed the prognostic value of SERPINF1 in three independent glioma datasets. Next, we explored the molecular functions and transcriptional regulation of SERPINF1 at the single-cell level. Moreover, in vitro experiments were conducted to evaluate the roles of SERPINF1 in the proliferation, invasion, migration, and stemness of glioma cells. Our results showed that a higher expression of SERPINF1 correlated with a poor overall survival rate in glioma patients (hazard ratio: 4.061 in TCGA, 2.017 in CGGA, and 1.675 in GSE16011, p < 0.001). Besides, SERPINF1 knockdown could suppress the proliferation, invasion, and migration of glioma cells in vitro. In addition, SERPINF1 expression was significantly upregulated in glioma stem cells (GSCs) compared to parental glioma cells. Knocking down SERPINF1 impaired the sphere formation of GSC-A172 and GSC-LN18. Bioinformatics analysis revealed that Notch signaling activation was closely associated with high SERPINF1 expression at the single-cell level. Furthermore, STAT1, CREM, and NR2F2 may participate in the transcriptional regulation of SERPINF1 in glioma. Overall, our results suggest that SERPINF1 may be a candidate prognostic predictor and potential therapeutic target for glioma.
Open AccessSERPINF1 Mediates Tumor Progression and Stemness in Glioma
Serpin family F member 1 (SERPINF1) reportedly plays multiple roles in various tumors; however, its clinical significance and molecular functions in glioma have been largely understudied. In the present study, we analyzed the prognostic value of SERPINF1 in three independent glioma datasets. Next, we explored the molecular functions and transcriptional regulation of SERPINF1 at the single-cell level. Moreover, in vitro experiments were conducted to evaluate the roles of SERPINF1 in the proliferation, invasion, migration, and stemness of glioma cells. Our results showed that a higher expression of SERPINF1 correlated with a poor overall survival rate in glioma patients (hazard ratio: 4.061 in TCGA, 2.017 in CGGA, and 1.675 in GSE16011, p < 0.001). Besides, SERPINF1 knockdown could suppress the proliferation, invasion, and migration of glioma cells in vitro. In addition, SERPINF1 expression was significantly upregulated in glioma stem cells (GSCs) compared to parental glioma cells. Knocking down SERPINF1 impaired the sphere formation of GSC-A172 and GSC-LN18. Bioinformatics analysis revealed that Notch signaling activation was closely associated with high SERPINF1 expression at the single-cell level. Furthermore, STAT1, CREM, and NR2F2 may participate in the transcriptional regulation of SERPINF1 in glioma. Overall, our results suggest that SERPINF1 may be a candidate prognostic predictor and potential therapeutic target for glioma.
- Open Access
Comprehensive Analysis of the Prognostic Value and Molecular Function of CRNDE in Glioma at Bulk and Single-Cell Levels
Colorectal neoplasia differentially expressed (CRNDE) is an oncogenic long noncoding RNA (lncRNA) overexpressed in diverse malignancies. Here, we comprehensively analyze the prognostic value and molecular function of CRNDE in glioma. Bulk RNA-sequencing data from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA), and single-cell RNA-sequencing data from the Tumor Immune Single-Cell Hub (TISCH) were analyzed. Kaplan–Meier survival analysis was applied to verify the prognostic value of CRNDE. Then, a nomogram based on multivariate Cox regression was established for individualized survival prediction. Subsequently, the expression characteristic and biological function of CRNDE were analyzed at the single-cell level. Lastly, the effects of CRNDE on the proliferation and invasion of glioma cell were explored in vitro. We discovered that CRNDE was a powerful marker for risk stratification of glioma patients. Regardless of the status of IDH and 1p/19q, CRNDE could effectively stratify patients’ prognosis. The nomogram that incorporated the CRNDE expression was proved to be a reliable tool for survival prediction. In addition, epithelial–mesenchymal transition may be the most important biological process regulated by CRNDE, which was identified at both the bulk and single-cell levels. Moreover, CRNDE knockdown significantly inhibited the proliferation and invasion of glioma cell. Overall, CRNDE is a vital oncogene and may be a valuable supplement to improve the clinical stratification of glioma.
Open AccessComprehensive Analysis of the Prognostic Value and Molecular Function of CRNDE in Glioma at Bulk and Single-Cell Levels
Colorectal neoplasia differentially expressed (CRNDE) is an oncogenic long noncoding RNA (lncRNA) overexpressed in diverse malignancies. Here, we comprehensively analyze the prognostic value and molecular function of CRNDE in glioma. Bulk RNA-sequencing data from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA), and single-cell RNA-sequencing data from the Tumor Immune Single-Cell Hub (TISCH) were analyzed. Kaplan–Meier survival analysis was applied to verify the prognostic value of CRNDE. Then, a nomogram based on multivariate Cox regression was established for individualized survival prediction. Subsequently, the expression characteristic and biological function of CRNDE were analyzed at the single-cell level. Lastly, the effects of CRNDE on the proliferation and invasion of glioma cell were explored in vitro. We discovered that CRNDE was a powerful marker for risk stratification of glioma patients. Regardless of the status of IDH and 1p/19q, CRNDE could effectively stratify patients’ prognosis. The nomogram that incorporated the CRNDE expression was proved to be a reliable tool for survival prediction. In addition, epithelial–mesenchymal transition may be the most important biological process regulated by CRNDE, which was identified at both the bulk and single-cell levels. Moreover, CRNDE knockdown significantly inhibited the proliferation and invasion of glioma cell. Overall, CRNDE is a vital oncogene and may be a valuable supplement to improve the clinical stratification of glioma.
- 28 May 2022
- Published by Springer Nature in Neurosurgical Review
- Vol. 45 (4) , 2961-2973
Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort
Hemorrhage of brainstem cavernous malformation (CM) would cause various symptoms and severe disability. The study aimed to elaborate on the 5-year actuarial cumulative hazard of symptomatic hemorrhage. Patients diagnosed in our institute between 2009 and 2013 were prospectively registered. All clinical data were obtained, follow-up was performed, and risk factors were evaluated. Four hundred sixty-eight patients (217 female, 46.4%) were included in the study with a median follow-up duration of 79.0 months. A total of 137 prospective hemorrhages occurred in 107 patients (22.9%) during 1854.0 patient-years. Multivariate Cox analysis found age ≥ 55 years (hazard ratio (HR) 2.166, p = 0.002), DVA (HR 1.576, p = 0.026), superficial-seated location (HR 1.530, p = 0.047), and hemorrhage on admission (HR 2.419, p = 0.026) as independent risk factors for hemorrhage. The 5-year cumulative hazard of hemorrhage was 30.8% for the overall cohort, 47.8% for 60 patients with age ≥ 55 years, 43.7% for 146 patients with DVA, 37.9% for 272 patients with superficial-seated lesions, and 37.2% for 341 patients with hemorrhage on admission. As a stratified analysis, within subcohort of 341 patients with a hemorrhagic presentation, age ≥ 55 years (HR 3.005, p < 0.001), DVA (HR 1.801, p = 0.010), and superficial-seated location (HR 2.276, p = 0.001) remained independently significant. The 5-year cumulative hazard of hemorrhage was 52.0% for 119 patients with both DVA and hemorrhagic presentation. The 5-year cumulative hemorrhagic risk was 30.8% and was higher in subgroups if harboring risk factors that helped to predict potential hemorrhagic candidates and were useful for treatment decision-making. Clinical Trial Registration-URL: http://www.chictr.org.cn Unique identifier: ChiCTR-POC-17011575.
- 28 May 2022
- Published by Springer Nature in Neurosurgical Review
- Vol. 45 (4) , 2961-2973
Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort
Hemorrhage of brainstem cavernous malformation (CM) would cause various symptoms and severe disability. The study aimed to elaborate on the 5-year actuarial cumulative hazard of symptomatic hemorrhage. Patients diagnosed in our institute between 2009 and 2013 were prospectively registered. All clinical data were obtained, follow-up was performed, and risk factors were evaluated. Four hundred sixty-eight patients (217 female, 46.4%) were included in the study with a median follow-up duration of 79.0 months. A total of 137 prospective hemorrhages occurred in 107 patients (22.9%) during 1854.0 patient-years. Multivariate Cox analysis found age ≥ 55 years (hazard ratio (HR) 2.166, p = 0.002), DVA (HR 1.576, p = 0.026), superficial-seated location (HR 1.530, p = 0.047), and hemorrhage on admission (HR 2.419, p = 0.026) as independent risk factors for hemorrhage. The 5-year cumulative hazard of hemorrhage was 30.8% for the overall cohort, 47.8% for 60 patients with age ≥ 55 years, 43.7% for 146 patients with DVA, 37.9% for 272 patients with superficial-seated lesions, and 37.2% for 341 patients with hemorrhage on admission. As a stratified analysis, within subcohort of 341 patients with a hemorrhagic presentation, age ≥ 55 years (HR 3.005, p < 0.001), DVA (HR 1.801, p = 0.010), and superficial-seated location (HR 2.276, p = 0.001) remained independently significant. The 5-year cumulative hazard of hemorrhage was 52.0% for 119 patients with both DVA and hemorrhagic presentation. The 5-year cumulative hemorrhagic risk was 30.8% and was higher in subgroups if harboring risk factors that helped to predict potential hemorrhagic candidates and were useful for treatment decision-making. Clinical Trial Registration-URL: http://www.chictr.org.cn Unique identifier: ChiCTR-POC-17011575.
- Open Access
- 18 March 2021
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 6 (4) , 501-510
Neurological outcomes of untreated brainstem cavernous malformations in a prospective observational cohort and literature review
Background Haemorrhages of brainstem cavernous malformations (CMs) can lead to neurological deficits, the natural history of which is uncertain. The study aimed to evaluate the neurological outcomes of untreated brainstem CMs and to identify the adverse factors associated with worsened outcomes. Methods From 2009 to 2015, 698 patients (321 women) with brainstem CMs were entered into the prospective cohort after excluding patients lost to follow-up (n=43). All patients were registered, clinical data were collected and scheduled follow-up was performed. Results After a median follow-up of 60.9 months, prospective haemorrhages occurred in 167 patients (23.9%). The mean modified Rankin Scale scores at enrolment and at censoring time were 1.6 and 1.2. Neurological status was improved, unchanged and worsened in 334 (47.9%), 293 (42.0%) and 71 (10.2%) patients, respectively; 233 (33.4%) recovered to normal levels. Lesions crossing the axial midpoint (relative risk (RR) 2.325, p=0.003) and developmental venous anomaly (DVA) (RR 1.776, p=0.036) were independently significantly related to worsened outcomes. The percentage of worsened outcomes was 5.3% (18 of 337) in low-risk patients (neither DVA nor crossing the axial point) and increased to 26.0% (13 of 50) in high-risk patients (with both DVA and crossing the axial point). The percentage of worsened outcomes significantly increased as the number of prospective haemorrhages increased (from 1.5% (8 of 531, if 0 prospective ictus) to 37.5% (48 of 128, if 1 ictus) and 38.5% (15 of 39, if >1 ictus)). Conclusions The neurological outcomes of untreated brainstem CMs were improved/unchanged in majority of patients (89.8%) with a fatality rate of 1.7% in our cohort, which seemed to be favourable. Radiological features significantly predicted worsened outcomes. Our results provide evidence for clinical consultation and individualised treatment. The referral bias of our cohort was underlined.
- 18 March 2021
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 6 (4) , 501-510
Open AccessNeurological outcomes of untreated brainstem cavernous malformations in a prospective observational cohort and literature review
Background Haemorrhages of brainstem cavernous malformations (CMs) can lead to neurological deficits, the natural history of which is uncertain. The study aimed to evaluate the neurological outcomes of untreated brainstem CMs and to identify the adverse factors associated with worsened outcomes. Methods From 2009 to 2015, 698 patients (321 women) with brainstem CMs were entered into the prospective cohort after excluding patients lost to follow-up (n=43). All patients were registered, clinical data were collected and scheduled follow-up was performed. Results After a median follow-up of 60.9 months, prospective haemorrhages occurred in 167 patients (23.9%). The mean modified Rankin Scale scores at enrolment and at censoring time were 1.6 and 1.2. Neurological status was improved, unchanged and worsened in 334 (47.9%), 293 (42.0%) and 71 (10.2%) patients, respectively; 233 (33.4%) recovered to normal levels. Lesions crossing the axial midpoint (relative risk (RR) 2.325, p=0.003) and developmental venous anomaly (DVA) (RR 1.776, p=0.036) were independently significantly related to worsened outcomes. The percentage of worsened outcomes was 5.3% (18 of 337) in low-risk patients (neither DVA nor crossing the axial point) and increased to 26.0% (13 of 50) in high-risk patients (with both DVA and crossing the axial point). The percentage of worsened outcomes significantly increased as the number of prospective haemorrhages increased (from 1.5% (8 of 531, if 0 prospective ictus) to 37.5% (48 of 128, if 1 ictus) and 38.5% (15 of 39, if >1 ictus)). Conclusions The neurological outcomes of untreated brainstem CMs were improved/unchanged in majority of patients (89.8%) with a fatality rate of 1.7% in our cohort, which seemed to be favourable. Radiological features significantly predicted worsened outcomes. Our results provide evidence for clinical consultation and individualised treatment. The referral bias of our cohort was underlined.